Potential Application of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Polycystic Ovary Syndrome and Infertile Patients with Obesity

doi:10.12280/gjszjk.20210103

Abstract

Abstract:

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenemia, oligo/anovulation, polycystic ovarian changes and impaired fertility. It is the most common cause of anovulatory infertility in women of childbearing age. Most of PCOS patients are accompanied by obesity, while obesity also has a negative impact on fertility. Glucagon-like peptide-1 (GLP-1) as an important gastrointestinal hormone plays an important role in the obesity and progression of PCOS. This review summarizes the mechanism of PCOS and infertility with obese/ overweight and the change of secretion pattern of GLP-1 in those PCOS women with obese. This review will provide the references that GLP-1 receptor agonists (GLP-1RA) can be used in the treatment of PCOS and infertile patients with obesity.

Key words: Glucagon-like peptide 1, Glucagon-like peptide-1 receptor, Polycystic ovary syndrome, Obesity, Infertility, female, Reproductive techniques, assisted

YANG Ze-xin, WANG Jun-chao. Potential Application of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Polycystic Ovary Syndrome and Infertile Patients with Obesity[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(5): 436-440.

References 36

[1]	Salvestrini V, Sell C, Lorenzini A. Obesity May Accelerate the Aging Process[J]. Front Endocrinol(Lausanne), 2019, 10:266. doi: 10.3389/fendo.2019.00266. doi: 10.3389/fendo.2019.00266
[2]	田园园, 石玉华. 体重指数对辅助生殖技术助孕治疗的影响[J]. 现代妇产科进展, 2020, 29(4):317-318. doi: 10.13283/j.cnki.xdfckjz.2020.04.037. doi: 10.13283/j.cnki.xdfckjz.2020.04.037
[3]	Joham AE, Palomba S, Hart R. Polycystic Ovary Syndrome, Obesity, and Pregnancy[J]. Semin Reprod Med, 2016, 34(2):93-101. doi: 10.1055/s-0035-1571195. doi: 10.1055/s-0035-1571195 pmid: 26854709
[4]	Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment[J]. Nat Rev Endocrinol, 2018, 14(5):270-284. doi: 10.1038/nrendo.2018.24. doi: 10.1038/nrendo.2018.24 pmid: 29569621
[5]	Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact[J]. Trends Endocrinol Metab, 2015, 26(3):136-143. doi: 10.1016/j.tem.2014.12.003. doi: 10.1016/j.tem.2014.12.003 URL
[6]	Silvestris E, de Pergola G, Rosania R, et al. Obesity as disruptor of the female fertility[J]. Reprod Biol Endocrinol, 2018, 16(1):22. doi: 10.1186/s12958-018-0336-z. doi: 10.1186/s12958-018-0336-z URL
[7]	Kudesia R, Wu H, Hunter Cohn K, et al. The effect of female body mass index on in vitro fertilization cycle outcomes: a multi-center analysis[J]. J Assist Reprod Genet, 2018, 35(11):2013-2023. doi: 10.1007/s10815-018-1290-6. doi: 10.1007/s10815-018-1290-6 URL
[8]	Mills G, Badeghiesh A, Suarthana E, et al. Associations between polycystic ovary syndrome and adverse obstetric and neonatal outcomes: a population study of 9.1 million births[J]. Hum Reprod, 2020, 35(8):1914-1921. doi: 10.1093/humrep/deaa144. doi: 10.1093/humrep/deaa144 URL
[9]	Rehman R, Mehmood M, Ali R, et al. Influence of body mass index and polycystic ovarian syndrome on ICSI/IVF treatment outcomes: A study conducted in Pakistani women[J]. Int J Reprod Biomed, 2018, 16(8):529-534.
[10]	Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists[J]. J Clin Endocrinol Metab, 2020, 105(8):e2695-2709. doi: 10.1210/clinem/dgaa285. doi: 10.1210/clinem/dgaa285 URL
[11]	Boots CE, Swanson AC, Jungheim ES. Infertility: a weight-bearing exercise?[J]. Fertil Steril, 2020, 114(5):964-965. doi: 10.1016/j.fertnstert.2020.08.006. doi: 10.1016/j.fertnstert.2020.08.006 URL
[12]	Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypojournal of PCOS as Functional Ovarian Hyperandrogenism Revisited[J]. Endocr Rev, 2016, 37(5):467-520. doi: 10.1210/er.2015-1104. doi: 10.1210/er.2015-1104 pmid: 27459230
[13]	苗继文, 程波, 李娜, 等. 脑肠轴调节机制的研究进展[J]. 中华神经医学杂志, 2020, 19(4):422-426. doi: 10.3760/cma.j.cn115354-20190506-00252. doi: 10.3760/cma.j.cn115354-20190506-00252
[14]	Liang Z, Di N, Li L, et al. Gut microbiota alterations reveal potential gut-brain axis changes in polycystic ovary syndrome[J]. J Endocrinol Invest, 2021, 44(8):1727-1737. doi: 10.1007/s40618-020-01481-5. doi: 10.1007/s40618-020-01481-5 pmid: 33387350
[15]	He FF, Li YM. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: a review[J]. J Ovarian Res, 2020, 13(1):73. doi: 10.1186/s13048-020-00670-3. doi: 10.1186/s13048-020-00670-3 URL
[16]	Li MM, Madara JC, Steger JS, et al. The Paraventricular Hypothalamus Regulates Satiety and Prevents Obesity via Two Genetically Distinct Circuits[J]. Neuron, 2019, 102(3):653-667.e6. doi: 10.1016/j.neuron.2019.02.028. doi: 10.1016/j.neuron.2019.02.028 URL
[17]	Romualdi D, Immediata V, De Cicco S, et al. Neuroendocrine Regulation of Food Intake in Polycystic Ovary Syndrome[J]. Reprod Sci, 2018, 25(5):644-653. doi: 10.1177/1933719117728803. doi: 10.1177/1933719117728803 pmid: 28874103
[18]	Ma J, Lin TC, Liu W. Gastrointestinal hormones and polycystic ovary syndrome[J]. Endocrine, 2014, 47(3):668-678. doi: 10.1007/s12020-014-0275-1. doi: 10.1007/s12020-014-0275-1 URL
[19]	Ilie IR. Neurotransmitter, neuropeptide and gut peptide profile in PCOS-pathways contributing to the pathophysiology, food intake and psychiatric manifestations of PCOS[J]. Adv Clin Chem, 2020, 96:85-135. doi: 10.1016/bs.acc.2019.11.004. doi: 10.1016/bs.acc.2019.11.004
[20]	Nishiyama Y, Hasegawa T, Fujita S, et al. Incretins modulate progesterone biosynjournal by regulating bone morphogenetic protein activity in rat granulosa cells[J]. J Steroid Biochem Mol Biol, 2018, 178:82-88. doi: 10.1016/j.jsbmb.2017.11.004. doi: 10.1016/j.jsbmb.2017.11.004 URL
[21]	Jensterle M, Janez A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective[J]. Hum Reprod Update, 2019, 25(4):504-517. doi: 10.1093/humupd/dmz019. doi: 10.1093/humupd/dmz019 pmid: 31260047
[22]	Vrbikova J, Hill M, Bendlova B, et al. Incretin levels in polycystic ovary syndrome[J]. Eur J Endocrinol, 2008, 159(2):121-127. doi: 10.1530/EJE-08-0097. doi: 10.1530/EJE-08-0097 pmid: 18511472
[23]	Ferjan S, Jensterle M, Oblak T, et al. An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity[J]. J Int Med Res, 2019, 47(10):4691-4700. doi: 10.1177/0300060519865351. doi: 10.1177/0300060519865351 URL
[24]	Bond RT, Nachef A, Adam C, et al. Obesity and Infertility: A Metabolic Assessment Strategy to Improve Pregnancy Rate[J]. J Reprod Infertil, 2020, 21(1):34-41.
[25]	Best D, Avenell A, Bhattacharya S. How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence[J]. Hum Reprod Update, 2017, 23(6):681-705. doi: 10.1093/humupd/dmx027. doi: 10.1093/humupd/dmx027 URL
[26]	Legro RS, Dodson WC, Kunselman AR, et al. Benefit of Delayed Fertility Therapy With Preconception Weight Loss Over Immediate Therapy in Obese Women With PCOS[J]. J Clin Endocrinol Metab, 2016, 101(7):2658-2666. doi: 10.1210/jc.2016-1659. doi: 10.1210/jc.2016-1659 URL
[27]	俞晓菡, 王雨露, 许笑阳, 等. 胰高血糖素样肽1受体激动剂在非酒精性脂肪性肝病治疗中的作用及相关机制[J]. 临床肝胆病杂志, 2021, 37(1):196-199. doi: 10.3969/j.issn.1001-5256.2021.01.043. doi: 10.3969/j.issn.1001-5256.2021.01.043
[28]	张宁倩, 王清. GLP-1受体激动剂/类似物治疗2型糖尿病的研究进展[J]. 实用药物与临床, 2019, 22(7):677-679. doi: 10.14053/j.cnki.ppcr.201907002. doi: 10.14053/j.cnki.ppcr.201907002
[29]	Frøssing S, Nylander M, Chabanova E, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial[J]. Diabetes Obes Metab, 2018, 20(1):215-218. doi: 10.1111/dom.13053. doi: 10.1111/dom.13053 pmid: 28681988
[30]	Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis[J]. Reprod Biomed Online, 2019, 39(2):332-342. doi: 10.1016/j.rbmo.2019.04.017. doi: S1472-6483(19)30394-3 pmid: 31229399
[31]	Dawson AJ, Sathyapalan T, Vince R, et al. The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome[J]. Front Endocrinol(Lausanne), 2019, 10:189. doi: 10.3389/fendo.2019.00189. doi: 10.3389/fendo.2019.00189
[32]	Kahal H, Kilpatrick E, Rigby A, et al. The effects of treatment with liraglutide on quality of life and depression in young obese women with PCOS and controls[J]. Gynecol Endocrinol, 2019, 35(2):142-145. doi: 10.1080/09513590.2018.1505848. doi: 10.1080/09513590.2018.1505848 pmid: 30599799
[33]	Nylander M, Frøssing S, Clausen HV, et al. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial[J]. Reprod Biomed Online, 2017, 35(1):121-127. doi: 10.1016/j.rbmo.2017.03.023. doi: S1472-6483(17)30194-3 pmid: 28479118
[34]	Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome[J]. Clin Endocrinol(Oxf), 2017, 87(6):767-774. doi: 10.1111/cen.13454. doi: 10.1111/cen.13454 URL
[35]	Salamun V, Jensterle M, Janez A, et al. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study[J]. Eur J Endocrinol, 2018, 179(1):1-11. doi: 10.1530/EJE-18-0175. doi: 10.1530/EJE-18-0175 pmid: 29703793
[36]	Abdalla MA, Deshmukh H, Atkin S, et al. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence[J]. Ther Adv Endocrinol Metab, 2021, 12:2042018821989238. doi: 10.1177/2042018821989238. doi: 10.1177/2042018821989238